Evidence map›Paper›PMID 36199014›Full record

SynthesisBMC pregnancy and childbirth2022

Women's values and preferences on low-molecular-weight heparin and pregnancy: a mixed-methods systematic review.

Montserrat León-García, Brittany Humphries, Andrea Maraboto, Montserrat Rabassa, Kasey R Boehmer, Lilisbeth Perestelo-Perez, Feng Xie, Irene Pelayo, Mark Eckman, Shannon Bates and 2 more

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in BMC pregnancy and childbirth, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 3 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

Montserrat León-GarcíaBiomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain. mleong@santpau.cat.
Brittany HumphriesCytel Inc, Toronto, ON, Canada.
Andrea MarabotoKnowledge and Evaluation Research Unit, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Montserrat RabassaBiomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
Kasey R BoehmerKnowledge and Evaluation Research Unit, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Lilisbeth Perestelo-PerezEvaluation Unit (SESCS), Canary Islands Health Service (SCS), Tenerife, Spain.
Feng XieDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Irene PelayoDepartment of Obstetrics and Gynecology, Ramón y Cajal Hospital, Madrid, Spain.
Mark EckmanDivision of General Internal Medicine and Center for Clinical Effectiveness, University of Cincinnati School of Medicine, Cincinnati, OH, USA.
Shannon BatesDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Anna SelvaDepartment of Pediatrics, Obstetrics, Gynaecology and Preventive Medicine, Universidad Autónoma de Barcelona, Barcelona, Spain.
Pablo Alonso-CoelloBiomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
McMaster University · CAMayo Clinic in Florida · USCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESInstituto Cajal · ESServicio Canario de la Salud · ESUniversitat Autònoma de Barcelona · ESUniversity of Cincinnati · US

Funding

Instituto de Salud Carlos III PI17/01874
6 · The paper itself

Abstract

backgroundVenous thromboembolism (VTE) in pregnancy is an important cause of maternal morbidity and mortality. Low-molecular-weight heparin (LMWH) is the cornerstone of prophylaxis and treatment of thrombotic events during pregnancy. LMWH has fewer adverse effects than other anticoagulants, does not cross the placenta, and is safe for the fetus. However, the use of LMWH during pregnancy is sensitive to womens' underlying preferences. The objective of this review is to systematically assess women's values and preferences research evidence on this topic.

methodsWe searched four electronic databases from inception to March 2022, and included studies examining values and preferences of using LMWH among pregnant women at risk of VTE. We followed a convergent integrated mixed-methods design to compare and contrast quantitative outcomes (utility and non-utility measures) and qualitative findings. We assessed the certainty of the values and preferences evidence with the GRADE approach for quantitative findings, and with GRADE-CERqual for qualitative evidence. Results were presented in a conjoint display.

resultsWe screened 3,393 references and identified seven eligible studies. The mixed methods analysis resulted in four themes. Datasets confirmed each other in that: 1) the majority of women consider that benefits of treatment outweigh the inconveniences of daily injections; and 2) main concerns around medication are safety and injections administration. Quantitative outcomes expanded on the qualitative findings in that: 3) participants who perceived a higher risk of VTE were more willing to take LMWH. Finally, we found a discrepancy between the datasets around: 4) the amount of information preferred to make the decision; however, qualitative data expanded to clarify that women prefer making informed decisions and receive support from their clinician in their decision-making process.

conclusionsWe are moderately confident that in the context of pregnancy, using LMWH is preferred by women given its net beneficial balance. Integrating data from different sources of evidence, and representing them in a jointly manner helps to identify patient's values and preferences. Our results may inform clinical practice guidelines and support shared decision-making process in the clinical encounter for the management of VTE in the context of pregnancy.

Indexed as

Pregnancy Complications, CardiovascularThrombosisVenous ThromboembolismAnticoagulantsFemaleHeparinHeparin, Low-Molecular-WeightHumansPregnancyAnticoagulantsHeparinHeparin, Low-Molecular-WeightLow-molecular-weight-heparinPregnancyValues and preferencesVenous thromboembolism

Identifiers

PMID36199014
PMCPMC9533610
OpenAlexW4301595303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.